Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04966741
Registration number
NCT04966741
Ethics application status
Date submitted
29/03/2021
Date registered
19/07/2021
Date last updated
4/10/2023
Titles & IDs
Public title
Setmelanotide in Pediatric Patients With Rare Genetic Diseases of Obesity
Query!
Scientific title
A Phase 3 Multi-Center, One-Year, Open-Label Study of Setmelanotide in Pediatric Patients Aged 2 to <6 Years of Age With Rare Genetic Causes of Obesity
Query!
Secondary ID [1]
0
0
RM-493-033
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bardet-Biedl Syndrome
0
0
Query!
POMC Deficiency Obesity
0
0
Query!
PCSK1 Deficiency Obesity
0
0
Query!
LEPR Deficiency Obesity
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Obesity
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Setmelanotide
Experimental: Setmelanotide - Investigational product: Setmelanotide,10 mg/mL in a sterile solution for Subcutaneous (SC) injection
Treatment: Drugs: Setmelanotide
All patients will begin treatment at a dose of 0.5 mg of setmelanotide per day. Patients will then increase their dose by 0.5 mg increments, every 2 weeks, until reaching their target maximum dose (not to exceed 2mg daily). The target maximum dose of setmelanotide used in this study will be based on the weight bands.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of patients demonstrating >0.2 decrease from baseline in body weight
Query!
Assessment method [1]
0
0
To evaluate the effect of setmelanotide on weight-related parameters by using measurement of decrease in body weight
Query!
Timepoint [1]
0
0
Baseline to Week 52
Query!
Primary outcome [2]
0
0
Mean percent change in BMI
Query!
Assessment method [2]
0
0
To evaluate the effect of setmelanotide on weight-related parameters by using the Body Mass Index measurement
Query!
Timepoint [2]
0
0
Baseline to Week 52
Query!
Secondary outcome [1]
0
0
Mean absolute change from baseline in BMI Z-score
Query!
Assessment method [1]
0
0
Mean absolute change from baseline in BMI Z-score by age and gender
Query!
Timepoint [1]
0
0
Baseline to Week 52
Query!
Secondary outcome [2]
0
0
Mean change in percent of the 95th percentile of BMI
Query!
Assessment method [2]
0
0
Mean change in percent of the 95th percentile of BMI by age and gender
Query!
Timepoint [2]
0
0
Baseline to Week 52
Query!
Secondary outcome [3]
0
0
Mean change in bone age
Query!
Assessment method [3]
0
0
Mean change in bone age
Query!
Timepoint [3]
0
0
Baseline to Week 52
Query!
Secondary outcome [4]
0
0
Mean change in Ages & Stages Questionnaires (ASQ®-3)
Query!
Assessment method [4]
0
0
Mean change in Ages & Stages Questionnaires score (ASQ®-3)
Query!
Timepoint [4]
0
0
Baseline to Week 52
Query!
Eligibility
Key inclusion criteria
Key
1. Patients must have obesity due to either:
1. POMC, PCSK1, or LEPR deficiency, confirmed by genetic testing demonstrating
biallelic variants that are interpreted as pathogenic, likely pathogenic, or of
undetermined significance (VUS) by the American College of Medical Genetics and
Genomics criteria (ACMG), or
2. BBS confirmed clinical and genetic diagnosis
2. Age between 2 to <6 years at the time of informed consent
3. Obesity, defined as BMI =97th percentile for age and gender AND body weight of at
least 15 kg at the time of enrollment.
4. Symptoms or behaviors of hyperphagia
5. Parent or guardian of study participant is able to understand and comply with the
requirements of the study (including once daily [QD] injection regimen and all other
study procedures) and is able to understand and sign the written consent/assent.
Key
Query!
Minimum age
2
Years
Query!
Query!
Maximum age
5
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
1. HbA1c >9.0% at screening
2. History of significant liver disease
3. Glomerular filtration rate (GFR) <60 mL/min/1.73 m2
4. History or close family history of melanoma, or patient history of oculocutaneous
albinism.
5. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions
(excluding non-invasive basal or squamous cell lesion)
6. Participation in any clinical study with an investigational drug/device within 3
months prior to the first day of dosing.
7. Previously enrolled in a clinical study involving setmelanotide or any previous
exposure to setmelanotide.
8. Significant hypersensitivity to any excipient in the study drug.
9. Inadequate hepatic function
10. Any other uncontrolled endocrine, metabolic or medical condition(s) known to impact
body weight
Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/02/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/09/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
12
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Sydney Children's Hospital - Randwick
Query!
Recruitment postcode(s) [1]
0
0
NSW 2031 - Randwick
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Colorado
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
New York
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Wisconsin
Query!
Country [4]
0
0
Spain
Query!
State/province [4]
0
0
Madrid
Query!
Country [5]
0
0
United Kingdom
Query!
State/province [5]
0
0
Cambridge
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Rhythm Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase 3 open-label, one-arm, clinical study to evaluate the efficacy, safety and
tolerability of setmelanotide over 1 year of treatment, in pediatric patients aged 2 to <6
years with obesity due to either biallelic variants of the POMC, PCSK1 or LEPR genes or
Bardet-Biedl Syndrome (BBS).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04966741
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
David Meeker, MD
Query!
Address
0
0
Rhythm Pharmaceuticals, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04966741
Download to PDF